Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | PPARG | P37231 | 8/20 | 0.40 |
| ▸ | PPARA | Q07869 | 8/20 | 0.40 |
| ▸ | THRA | P10827 | 7/20 | 0.39 |
| ▸ | THRB | P10828 | 7/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3141333 | 0.83 | SMN1; SMN2 (0.47) | SMN1; SMN2 | |
| SCHEMBL3140908 | 0.83 | TDP1 (0.48) | THRATHRB | |
| SCHEMBL442891 | 0.82 | SMN1; SMN2 (0.63) | SMN1; SMN2PPARGPPARA | |
| SCHEMBL8148046 | 0.76 | MAPT (0.42) | SMN1; SMN2THRATHRB | |
| SCHEMBL3138232 | 0.76 | SMN1; SMN2 (0.42) | SMN1; SMN2PPARGPPARATHRATHRB | |
| SCHEMBL11550284 | 0.75 | SMN1; SMN2 (0.67) | SMN1; SMN2PPARGPPARA | |
| SCHEMBL8431218 | 0.74 | SMN1; SMN2 (0.57) | SMN1; SMN2PPARGPPARA | |
| SCHEMBL3918815 | 0.74 | THRB (0.48) | THRATHRBPTPN1 | |
| SCHEMBL3925367 | 0.74 | MAPT (0.40) | SMN1; SMN2THRATHRB | |
| SCHEMBL4814937 | 0.74 | SMN1; SMN2 (0.74) | SMN1; SMN2PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004271-A1 | HETEROCYCLIC COMPOUNDS AS AGANIST FOR THE THYROID RECEPTOR | KARO BIO AB (SE) | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004271-A1 | HETEROCYCLIC COMPOUNDS AS AGANIST FOR THE THYROID RECEPTOR | TSHR, GHSR, TRHR | SMN1; SMN2 4757/4885PPARG 48/4885PPARA 293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.